Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kura Oncology (KURA) Interest & Investment Income (2023 - 2024)

Kura Oncology (KURA) has disclosed Interest & Investment Income for 3 consecutive years, with $6.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Interest & Investment Income rose 6.48% to $6.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $25.7 million, a 19.22% increase, with the full-year FY2025 number at $26.8 million, up 17.18% from a year prior.
  • Interest & Investment Income was $6.3 million for Q3 2025 at Kura Oncology, down from $7.9 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $7.9 million in Q1 2025 to a low of $2.9 million in Q1 2023.
  • A 3-year average of $5.2 million and a median of $5.5 million in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: soared 86.12% in 2024, then increased 6.48% in 2025.
  • Kura Oncology's Interest & Investment Income stood at $4.4 million in 2023, then grew by 29.5% to $5.7 million in 2024, then increased by 10.87% to $6.3 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Interest & Investment Income are $6.3 million (Q3 2025), $7.9 million (Q1 2025), and $5.7 million (Q4 2024).